Compare Nutrien Ltd (NTR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nutrien Ltd vs Repligen Corporation Common Stock — how do they compare? Nutrien Ltd trades at $70.38 (market cap $33.39B), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Nutrien Ltd is far larger — about 3× Repligen Corporation Common Stock's market cap, and Nutrien Ltd pays a 3.15% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nutrien Ltd for 60 Days and Repligen Corporation Common Stock for 0 Days on average.
| NTR | RGEN | |
|---|---|---|
Market Cap | $33.39B | $11.31B |
Volume | 2,147,139 | 1,216,919 |
Sector | Basic Materials | Health |
52-Week High | $83.94 | $194.57 |
52-Week Low | $53.64 | $102.87 |
Typical Hold Time | 60 Days | 0 Days |
Enterprise Value | $45.20B | $11.20B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nutrien (NTR) trades at $69.68, up 2.47% with mixed technical signals showing bearish momentum but oversold conditions. The company reported Q2 2026 earnings miss ($2.61 vs $2.70 expected) but maintains stable revenue growth projections. Strong institutional interest continues with BlackRock acquiring a $220 million position in Q2 2026, while analyst consensus remains positive with a $77.29 price target representing 11% upside potential.
The fertilizer producer faces near-term headwinds from potential Belarus potash imports but benefits from structural North American gas advantages. While technical indicators suggest caution, fundamental valuation metrics (P/E 14.11, P/S 1.19) appear reasonable given the company's market leadership position and improving profitability trends from 2024 lows.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nutrien Ltd
Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.
Read more on NTR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
